Table 1 Patient characteristics
Characteristics | All patients n = 200 (range or %) |
|---|---|
Age, years | 65 (38–88) |
Gender | Â |
 Male | 109 (54.5) |
 Female | 91 (45.5) |
Body mass index, kg/m2 | 20.1 (13.2–29.0) |
ECOG-PS | Â |
 0 | 141 (70.5) |
 1 | 57 (28.5) |
 2 | 2 (1.0) |
CA19-9, U/mL | 231.9 (0.1–19,500) |
CEA, ng/mL | 3.5 (0.5–135.1) |
Pathological diagnosis | Â |
 Yes | 132 (66.0) |
 No | 68 (34.0) |
Tumor size, mm | 36 (15–70) |
Major arterial invasion | Â |
 CA | 91 (45.5) |
 SMA | 37 (18.5) |
 CA and SMA | 72 (36.0) |
UICC T classification | Â |
 1–3 | 0 (0) |
 4 | 200 (100) |
UICC N classification | Â |
 0 | 137 (68.5) |
 1 | 60 (30.0) |
 2 | 3 (1.5) |
UICC stage | Â |
 I, II | 0 (0) |
 III | 200 (100) |
Bile duct invasion | Â |
 Positive | 30 (15.0) |
 Negative | 170 (85.0) |
Duodenal invasion | Â |
 Positive | 18 (9.0) |
 Negative | 182 (91.0) |
Anterior peripancreatic invasion | Â |
 Positive | 130 (65.0) |
 Negative | 70 (35.0) |
Posterior peripancreatic invasion | Â |
 Positive | 200 (100) |
 Negative | 0 (0) |
Venous invasion | Â |
 Positive | 182 (91.0) |
 Negative | 18 (9.0) |
Arterial invasion | Â |
 Positive | 200 (100) |
 Negative | 0 (0) |
Extrapancreatic nerve plexus invasion | Â |
 Positive | 200 (100) |
 Negative | 0 (0) |
Other organ invasion | Â |
 Positive | 9 (4.5) |
 Negative | 191 (95.5) |
Previous treatment | Â |
 Yes | 106 (53.0) |
  FOLFIRINOX | 6 (3.0) |
  GnP | 16 (8.0) |
  FOLFIRINOX and GnP | 51 (25.5) |
  Others | 33 (16.5) |
 No | 94 (47.0) |
Complete scheduled concurrent chemotherapy | Â |
 Yes | 140 (70.0) |
  GEM | 123 (61.5) |
  S1 | 17 (8.5) |
 No | 60 (30.0) |
  Incomplete GEM | 36 (18.0) |
  Incomplete S1 | 10 (5.0) |
  No concurrent chemotherapy | 14 (7.0) |
Median GTV volume, cc | 46.3 (4.7–205.6) |
Median CTV volume, cc | 189.6 (53.3–424.0) |
Median GTV V60GyE, % | 64.2 (25.2–100) |
Median CTV V60GyE, % | 61.2 (30.3–97.3) |